Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

• Post published:October 15, 2022
• Post category:Press Release

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

• Post published:September 21, 2022
• Post category:Press Release

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

• Post published:September 19, 2022
• Post category:Press Release

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

• Post published:September 13, 2022
• Post category:Press Release

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

• Post published:September 9, 2022
• Post category:Press Release

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

• Post published:September 2, 2022
• Post category:Press Release

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

• Post published:August 24, 2022
• Post category:Press Release

Algernon Pharmaceuticals Announces Private Placement

• Post published:August 20, 2022
• Post category:Press Release

Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

• Post published:August 3, 2022
• Post category:Press Release

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

• Post published:July 30, 2022
• Post category:Press Release